TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01570387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-21 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10-20 mg on days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10-20 mg on days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10-20 mg on days 1, 8, 15, and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10-20 mg on days 1, 8, 15, and 22
Study: NCT01469247

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Starting Dose 24 Gy in 2 Gy fractions.
Study: NCT05072899

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet rich plasm
Description: local injection of shoulder joint by platelet rich plasm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: local injection of shoulder joint by Hyaluronic acid
Study: NCT02103465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: transdermal patch
Study: NCT03401073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: Gamunex-C \[immune globulin injection (human) 10% caprylate/chromatography purified\] is a sterile solution of human immune globulin protein.
Study: NCT02103465

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: transdermal patch
Study: NCT01253421

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single-dose placebo capsule
Study: NCT02118610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-tetrahydropalmatine (30mg)
Description: Active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Placebo
Study: NCT04208763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem
Description: Inj Imipenem 1gm i.v. TDS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: Inj Imipenem 1gm i.v. TDS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline
Description: Inj Tigecycline 100mg stat f/b 50mg i.v. OD
Study: NCT06143189

Intervention type: OTHER
Group type: OTHER
Intervention: Hosting conditions
Description: Hosting conditions care~the patients are welcome by the nurse, whom talk and give the comfort needed by the patients before starting the treatments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hosting conditions
Description: Hosting conditions care~the patients are welcome by the nurse, whom talk and give the comfort needed by the patients before starting the treatments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital Clowns
Description: The HCs Palhaços D'Opital (PdO) have a program aiming to bring joy, affection and good mood to adults and elders in hospital environment. They work in pairs, dressed in colorful costumes and they prepared sketches in advance. Their performances recreate day-to-day situations (e.g., clowns trying to install a new TV screen; planning a wedding between the clowns and asking the public for their ideas), ending with specific closure, in order to indicate to the audience that the session had finished and to promote a positive environment after their departure. Each intervention lasted around 15 minutes.
Study: NCT04208763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Inj Tigecycline 100mg stat f/b 50mg i.v. OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMCSF
Description: Inj GM-CSF 500mcg s.c. OD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: Inj Colistin 9 MIU i.v. stat f/b 4.5 MIU i.v. BD
Study: NCT00621855

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: capsules, twice daily, 26 weeks treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: capsules, twice daily, 26 weeks treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: capsules, twice daily, 26 weeks treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: capsules, twice daily, 26 weeks treatment
Study: NCT01240057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fetal endoluminal tracheal occlusion
Description: percutaneous fetoscopy, positioning of endoluminal balloon at 27-30 weeks and whenever possible elective removal at 34 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: watchful waiting during pregnancy
Description: pregnancy surveillance for fetal wellbeing, development of polyhydramnios and cervical shortening
Study: NCT04586114

Intervention type: DRUG
Intervention: Corticosteroids and Derivatives
Description: Any systemic corticosteroid treatment administrated during ICU stay

Intervention type: DRUG
Intervention: Corticosteroids and Derivatives
Description: Any systemic corticosteroid treatment administrated during ICU stay
Study: NCT01269372

Intervention type: DEVICE
Group type: OTHER
Intervention: PillCam Colon 2
Description: Each subject will be required to follow a bowel preparation regimen and will undergo Capsule Endoscopy (CE).~Following capsule ingestion and depending on capsule progression through the digestive tract subjects will be required to take an additional volume of laxatives in order to enhance capsule propulsion and maintain adequate cleansing of the colon.

Intervention type: DEVICE
Group type: OTHER
Intervention: Colonoscopy
Description: The colonoscopy procedure will be scheduled approximately 4-6 weeks after the CE procedure, and the colonoscopy bowel preparation will be the same as the bowel preparation for CE.
Study: NCT04093518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: 2 transdermal patches to be changed twice a week for the duration of 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 transdermal patches to be changed twice a week for the duration of 16 weeks
Study: NCT03401073

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
Study: NCT03060850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010MA
Description: Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days
Study: NCT01719887

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Conservative treatment with functional brace.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operative treatment
Description: Operative treatment with open reduction and internal fixation using 4,5mm locking compression plate.
Study: NCT00657943

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: insulin detemir
Description: insulin as requested

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: insulin as requested

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: insulin detemir
Description: insulin as requested
Study: NCT01473810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vacc-4x low dose
Description: 80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vacc-4x medium dose
Description: 400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vacc-4x high dose
Description: 1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Zero dose
Description: 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
Study: NCT00657943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart + insulin aspart protamin
Description: insulin as requested

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: insulin aspart + insulin aspart protamin
Description: insulin as requested

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: insulin as requested

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin aspart
Description: insulin as requested
Study: NCT01924975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saphenous vein cannulation
Description: Intravenous cannulation to saphenous vein
Study: NCT01719887

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy is arranged to both groups at 3 and 9 wks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy is arranged to both groups at 3 and 9 wks.
Study: NCT01046630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: single infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: single infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single infusion
Study: NCT03532230

Intervention type: PROCEDURE
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: No specific OMT techniques will be required for the present study. However, data on the number of OMT sessions patients receive will be collected.
Study: NCT01223235

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
Description: A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
Study: NCT01529658

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal hypothermia
Description: Within 10 seconds of clamping the renal vessels, the kidney will be encased with saline ice slush for a period of 10 minutes. The slush will be created from sterile saline using an operating room slush machine. The slush is applied by the surgeon and lightly packed around the kidney to ensure complete coverage with at least a 2 cm layer. Slush removal is performed by the surgeon beginning at the 10 minute mark. Enough slush is removed to uncover the tumour area. Surgical incision of the kidney begins as soon as the tumour area is uncovered.~When reconstruction of the kidney is complete, the slush is completely removed from the surgical field and the clamps are removed from the renal vein and artery.
Study: NCT03851588

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is not given with a supplementary dose of dolutegravir 50 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir 50 mg
Description: Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is given with a supplementary dose of dolutegravir 50 mg.
Study: NCT01924975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saphenous vein cannulation
Description: Intravenous cannulation to saphenous vein

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound with a linear transducer (L15-7io)
Description: Portable, bed-side ultrasound to detect saphenous vein

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A 22 or 24 G intravenous catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A 22 or 24 G intravenous catheter
Study: NCT02587130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine administered in bolus by subcutaneous injection
Study: NCT00401323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel (XRP6976)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel (XRP6976)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil (5-FU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Study: NCT01030211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet transfusion
Description: 4 units of platelets for patients with platelet count \<20x10\^3/uL

Intervention type: OTHER
Group type: OTHER
Intervention: Supportive care
Description: Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure
Study: NCT03885219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel and S-1
Description: Nab-paclitaxel: 120 mg/m2 d1, 8, S-1:Body surface area \< 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 , \< 1.5 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14; repeat every 21 days.
Study: NCT01316991

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chewing Gum
Description: chewing gum will be provided

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No Gum
Description: no chewing gum will be provided
Study: NCT02654574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IADL administration by phone
Description: The administration of IADL questionnaire by phone consists of a collection of answers given by the caregiver during the interview with the research nurse, trained for this procedure. This method of procurement will be standardized with a listing support for the phone interview to obtain the same conditions for collection of data from a caregiver to another. Questions will be asked in the same order than the questionnaire collected with the reference procedure i.e. face-to-face interview at the Memory Clinic. The IADL questionnaires in paper format used during the ace-to-face interview and by phone will be identical.
Study: NCT00523978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Front® Cryoablation Catheter
Description: Experimental Subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci with the cryoablation catheter system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide or Sotalol or Propafenone
Description: Flecainide 200 mg / day Propafenone 450 mg / day Propafenone-SR 650 mg / day Sotalol 240 mg / day
Study: NCT01530958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CKD Registry
Description: Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:~* identify patients with CKD~* notify PCPs of a patients' CKD status~* provide PCP outreach with NKDEP guidelines and patient educational materials

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CKD Registry
Description: Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:~* identify patients with CKD~* notify PCPs of a patients' CKD status~* provide PCP outreach with NKDEP guidelines and patient educational materials

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ATSM + Health Coach
Description: Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATSM + Health Coach
Description: Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Primary care providers will manage their patients with CKD per usual care.~Patients will receive usual care.
Study: NCT01350323

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous sample
Description: Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous sample
Description: Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous sample
Description: Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aqueous sample
Description: Aqueous sample (0.1ml)
Study: NCT03261830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Primary intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: For use in Pre-operative Antibiotics arm in cases of documented allergy to primary intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo Intervention
Study: NCT02850601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
Study: NCT02443584

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacogenetic testing
Description: pharmacogenetic testing for anti-depressant/anti-psychotic medications

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacogenetic testing
Description: pharmacogenetic testing for anti-depressant/anti-psychotic medications
Study: NCT02130531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emixustat HCl Tablet
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emixustat HCl Tablet
Description: Tablet for oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Tablet
Description: Tablet for oral administration
Study: NCT02850601

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
Study: NCT03864978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin delayed release 400 mg tablet
Description: Rifaximin delayed release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin delayed release 400 mg tablet
Description: Rifaximin delayed release
Study: NCT00809315

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessment
Description: Cognitive, academic achievement, and mental health screening assessment and report.
Study: NCT03864978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin delayed release 400 mg tablet
Description: Rifaximin delayed release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00809315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment
Description: Cognitive, academic achievement, and mental health screening assessment and report.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fostering Healthy Futures (FHF)
Description: Weekly therapeutic skill groups and mentoring over a 9-month period.
Study: NCT01999426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Airway clearance intervention
Description: Both respiratory and non-respiratory on-call physiotherapists provide similar airway clearance treatments, the precise components and delivery of which will vary between physiotherapists

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Airway clearance intervention
Description: Both respiratory and non-respiratory on-call physiotherapists provide similar airway clearance treatments, the precise components and delivery of which will vary between physiotherapists
Study: NCT02108288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-1085EL ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carteolol long-acting ophthalmic solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution
Study: NCT03323164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate
Description: Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine Tartrate
Description: Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
Study: NCT03953807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Intravitreal Implant
Description: Implant 700 μg
Study: NCT01593917

Intervention type: DEVICE
Intervention: Trifecta™ Valve
Description: Aortic valve replacement with the Trifecta™ aortic bioprosthesis.
Study: NCT00706355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217903
Description: Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
Study: NCT03648619

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Semi whole-body MRI
Description: Single semi-automatic, semi whole-body MRI protocol (Dot engine)